Cargando…
Novel aptamer to von Willebrand factor A1 domain (TAGX-0004) shows total inhibition of thrombus formation superior to ARC1779 and comparable to caplacizumab
Von Willebrand factor (VWF) is a blood glycoprotein that plays an important role in platelet thrombus formation through interaction between its A1 domain and platelet glycoprotein Ib. ARC1779, an aptamer to the VWF A1 domain, was evaluated in a clinical trial for acquired thrombotic thrombocytopenic...
Autores principales: | Sakai, Kazuya, Someya, Tatsuhiko, Harada, Kaori, Yagi, Hideo, Matsui, Taei, Matsumoto, Masanori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604614/ https://www.ncbi.nlm.nih.gov/pubmed/33131252 http://dx.doi.org/10.3324/haematol.2019.235549 |
Ejemplares similares
-
The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor-mediated ex vivo platelet function in ST-elevation and non-ST-elevation acute myocardial infarction
por: Spiel, Alexander O, et al.
Publicado: (2008) -
Aptamers Targeting Von Willebrand Factor: What and Why?
por: Schutgens, Roger E. G.
Publicado: (2023) -
Potent and rapid reversal of the von Willebrand factor inhibitor aptamer BT200
por: Zhu, Shuhao, et al.
Publicado: (2020) -
Rapid Restoration of Thrombus Formation and High-Molecular-Weight von Willebrand Factor Multimers in Patients with Severe Aortic Stenosis After Valve Replacement
por: Yamashita, Keigo, et al.
Publicado: (2016) -
Hemophilia and von Willebrand disease: Factor VIII and von Willebrand factor
por: Sharma, Prashant
Publicado: (2019)